ECT2 has been found to be up-regulated during transition to malignancy in a mouse model [59], to be amplified and overexpressed in non-small cell lung cancer [60], and to have an elevated expression in colorectal cancer [61]. Here, ECT2 is linked to non-small cell lung carcinoma.